rasagiline

monoamine oxidase B ; Homo sapiens







179 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
101 20022592 A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. 2010 May 1 2
102 20195940 [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. 2010 Mar 1
103 20197647 Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. 2010 1
104 20236308 Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease. 2010 Sep 1
105 20445015 Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. 2010 Dec 4
106 20517484 The role of rasagiline in the treatment of Parkinson's disease. 2010 May 25 3
107 20600573 Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. 2010 Nov 4
108 20624440 Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. 2010 Nov 1
109 20977789 [Rasagiline is not for all Parkinson disease patients: the ADAGIO study]. 2010 1
110 20979033 [Rasagiline: effectiveness and protection in Parkinson's disease]. 2010 Nov 1 1
111 21389939 [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)]. 2010 2
112 23908775 Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential. 2010 Jul 3
113 19110207 Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. 2009 Jan 1
114 19384601 Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. 2009 Apr 1
115 19526291 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. 2009 Aug 5
116 19673610 Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. 2009 Aug 1
117 19733607 Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. 2009 Nov 13 1
118 19753135 Role of rasagiline in treating Parkinson's disease: Effect on disease progression. 2009 Aug 2
119 18067186 Rasagiline improves freezing in a patient with primary progressive freezing gait. 2008 Feb 15 1
120 18072817 Spotlight on rasagiline in Parkinson's disease. 2008 4
121 18307054 [Rasagiline in Parkinson's disease]. 2008 May 1
122 18668620 Medical treatment of freezing of gait. 2008 1
123 18678789 Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. 2008 Sep 1
124 18833504 [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. 2008 Oct 2
125 18937611 The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. 2008 Nov 2
126 18952510 Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study. 2008 Nov 15 1
127 19004128 [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease]. 2008 1
128 17055733 Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. 2007 Jan 2
129 17347320 The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. 2007 Jun 1
130 17495756 Advances in the pharmacologic management of early Parkinson disease. 2007 May 2
131 17545750 Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. 2007 May-Jun 2
132 17630819 Medical management of levodopa-associated motor complications in patients with Parkinson's disease. 2007 1
133 17635668 Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. 2007 Oct 2
134 17683172 Rasagiline: a review of its use in the management of Parkinson's disease. 2007 4
135 17702535 Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. 2007 1
136 18035186 Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. 2007 Sep 2
137 18041937 Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. 2007 Dec 1
138 18267281 New strategies in motor parkinsonism. 2007 1
139 18488080 Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. 2007 Jun 3
140 16425668 Drugs in development for Parkinson's disease: an update. 2006 Jan 1
141 16450340 Rasagiline improves quality of life in patients with early Parkinson's disease. 2006 May 1
142 16451296 Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. 2006 Feb 1
143 16675649 Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. 2006 May 15 5
144 16717254 Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. 2006 May 23 1
145 16717255 Clinical trials with rasagiline: evidence for short-term and long-term effects. 2006 May 23 1
146 16828804 Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. 2006 Oct 25 1
147 16856145 Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. 2006 Oct 2
148 16935943 A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. 2006 Oct 1
149 17017568 Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. 2006 1
150 17296539 Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. 2006 Dec 1